59: Zeng H, Horie K, Madisen L, Pavlova MN, Gragerova G, Rohde AD, Schimpf BA, Liang Y, Ojala E, Kramer F, Roth P, Slobodskaya O, Dolka I, Southon EA, Tessarollo L, Bornfeldt KE, Gragerov A, Pavlakis GN, Gaitanaris GA. An inducible and reversible mouse genetic rescue system.  PLoS Genet. 2008 May 9;4(5):e1000069. (Abstract)

58:  Johansson F, Kramer F, Barnhart S, Kanter JE, Vaisar T, Merrill RD, Geng L, Oka K, Chan L, Chait A, Heinecke JW, Bornfeldt KE. Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2082-7. (Abstract)

57: Kanter JE, Johansson F, LeBoeuf RC, Bornfeldt KE.  Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circ Res. 2007 Mar 30;100(6):769-81. (Abstract)

56: Shen X, Bornfeldt KE.   Mouse models for cardiovascular complications of type 1 diabetes. Ann N Y Acad Sci. 2007 Apr;1103:202-17. (Abstract)

55: Askari B, Kanter JE, Sherrid AM, Golej DL, Bender AT, Liu J, Hsueh WA, Beavo JA, Coleman RA, Bornfeldt KE. Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-{gamma}-independent mechanism in human arterial smooth muscle cells and macrophages. Diabetes. 2007 Apr;56(4):1143-52. (Abstract)

54: Bornfeldt KE.  A single second messenger: several possible cellular responses depending on distinct subcellular pools. Circ Res. 2006 Oct 13;99(8):790-2.

53: MacDougall ED, Kramer F, Polinsky P, Barnhart S, Askari B, Johansson F, Varon R, Rosenfeld ME, Oka K, Chan L, Schwartz SM, Bornfeldt KE.  Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice. Am J Pathol. 2006 Jun;168(6):2064-73. (Abstract)

52: Bornfeldt KE. Nuclear signaling in smooth muscle cells: cyclic nucleotide phosphodiesterase 1A moves in. Circ Res. 2006 Mar 31;98(6):720-2.

51: Nitert MD, Chisalita SI, Olsson K, Bornfeldt KE, Arnqvist HJ. IGF-I/insulin hybrid receptors in human endothelial cells. Mol Cell Endocrinol. 2005 Jan 14;229:31-7. (Abstract)

50: Lamharzi N, Renard CB, Kramer F, Pennathur S, Heinecke JW, Chait A, Bornfeldt KE. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. Diabetes. 2004 Dec;53:3217-25. (Abstract)

49: Renard CB, Kramer F, Johansson F, Lamharzi N, Tannock LR, von Herrath MG, Chait A, Bornfeldt KE. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions.  J Clin Invest. 2004 Sep;114:659-68. (Abstract)

48: Marshek DG, Bornfeldt KE, Coleman RA, Berger J, Bernlohr DA, Black P, DiRusso CC, Farber SA, Guo W, Hashimoto N, Khodiyar V, Kuypers FA, Maltais LJ, Nebert DW, Renieri A, Schaffer JE, Stahl A, Watkins PA, Vasiliou V, Yamamoto TT. Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene family. J Lipid Res. 2004 Oct;45:1958-61. (Abstract)

47: Oram JF, Bornfeldt KE. Direct effects of long-chain non-esterified fatty acids on vascular cells and their relevance to macrovascular complications of diabetes. Front Biosci. 2004 May 1;9:1240-53. (Abstract)

46: Renard CB, Askari B, Suzuki LA, Kramer F, Bornfeldt KE. Oleate, not ligands of the receptor for advanced glycation end-products, promotes proliferation of human arterial smooth muscle cells.  Diabetologia. 2003 Dec;46:1676-87. (Abstract)

45: Schwartz SM, Bornfeldt KE. How does diabetes accelerate atherosclerotic plaque rupture and arterial occlusion? Front Biosci. 2003 Sep 1;8:s1371-83. (Abstract)

44: Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res. 2003 Aug 22;93(4):280-91. (Abstract)

43: Bornfeldt KE. The cyclin-dependent kinase pathway moves forward. Circ Res. 2003 Mar 7;92(4):345-7. (Abstract)

42: Yokota T, Ma RC, Park JY, Isshiki K, Sotiropoulos KB, Rauniyar RK, Bornfeldt KE, King GL. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes. 2003 Mar;52(3):838-45. (Abstract)

41: Askari B, Renard CB, Bornfeldt KE. Regulation of smooth muscle cell accumulation in diabetes-accelerated atherosclerosis. Histol Histopathol. 2002 Oct;17(4):1317-28. (Abstract)

40: Askari B, Carroll MA, Capparelli M, Kramer F, Gerrity RG, Bornfeldt KE. Oleate and linoleate enhance the growth-promoting effects of insulin-like growth factor-I through a phospholipase D-dependent pathway in arterial smooth muscle cells. J Biol Chem. 2002 Sep 27;277(39):36338-44. Epub 2002 Jul 22. (Abstract)

39: Rybalkin SD, Rybalkina I, Beavo JA, Bornfeldt KE. Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res. 2002 Feb 8;90(2):151-7. (Abstract)

38: Lin G, Bornfeldt KE. Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux. Biochem Biophys Res Commun. 2002 Jan 18;290(2):663-9. (Abstract)

37: Renard CB, Bornfeldt KE. Human arterial smooth muscle cells rapidly deplete cell culture media of glucose. Diabetologia. 2001 Aug;44(8):1067-8. (Abstract)

36: Wong ST, Baker LP, Trinh K, Hetman M, Suzuki LA, Storm DR, Bornfeldt KE. Adenylyl cyclase 3 mediates prostaglandin E(2)-induced growth inhibition in arterial smooth muscle cells. J Biol Chem. 2001 Sep 7;276(36):34206-12. Epub 2001 Jun 29. (Abstract)

35: Suzuki LA, Poot M, Gerrity RG, Bornfeldt KE. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. Diabetes. 2001 Apr;50(4):851-60. (Abstract)

34: Zhao AZ, Shinohara MM, Huang D, Shimizu M, Eldar-Finkelman H, Krebs EG, Beavo JA, Bornfeldt KE. Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. J Biol Chem. 2000 Apr 14;275(15):11348-54. (Abstract)

33: Koyama H, Bornfeldt KE, Fukumoto S, Nishizawa Y. Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol. 2001 Jan;186(1):1-10. (Abstract)

32: Bornfeldt KE. Stressing Rac, Ras, and downstream heat shock protein 70. Circ Res. 2000 Jun 9;86(11):1101-3. Review. (Abstract)

31: Rybalkin SD, Bornfeldt KE. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Thromb Haemost. 1999 Aug;82(2):424-34. (Abstract)

30: O'Doherty RM, Anderson PR, Zhao AZ, Bornfeldt KE, Newgard CB. Sparing effect of leptin on liver glycogen stores in rats during the fed-to-fasted transition. Am J Physiol. 1999 Sep;277(3 Pt 1):E544-50. (Abstract)

29: Bornfeldt KE, Krebs EG. Crosstalk between protein kinase A and growth factor receptor signaling pathways in arterial smooth muscle. Cell Signal. 1999 Jul;11(7):465-77. (Abstract)

28: Zhao AZ, Bornfeldt KE, Beavo JA. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest. 1998 Sep 1;102(5):869-73. (Abstract)

27: Sonnenburg WK, Rybalkin SD, Bornfeldt KE, Kwak KS, Rybalkina IG, Beavo JA. Identification, quantitation, and cellular localization of PDE1 calmodulin-stimulated cyclic nucleotide phosphodiesterases. Methods. 1998 Jan;14(1):3-19. (Abstract)

26: Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hanson K, Krebs EG, Beavo JA. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest. 1997 Nov 15;100(10):2611-21. (Abstract)

25: Graves LM, Bornfeldt KE, Krebs EG. Historical perspectives and new insights involving the MAP kinase cascades. Adv Second Messenger Phosphoprotein Res. 1997;31:49-62. (Abstract)

24: Bornfeldt KE, Campbell JS, Koyama H, Argast GM, Leslie CC, Raines EW, Krebs EG, Ross R. The mitogen-activated protein kinase pathway can mediate growth inhibition and proliferation in smooth muscle cells. Dependence on the availability of downstream targets. J Clin Invest. 1997 Aug 15;100(4):875-85. (Abstract)

23: Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 1996 Dec 13;87(6):1069-78. (Abstract)

22: Graves LM, Bornfeldt KE, Sidhu JS, Argast GM, Raines EW, Ross R, Leslie CC, Krebs EG. Platelet-derived growth factor stimulates protein kinase A through a mitogen-activated protein kinase-dependent pathway in human arterial smooth muscle cells. J Biol Chem. 1996 Jan 5;271(1):505-11. (Abstract)

21: Arnqvist HJ, Bornfeldt KE, Chen Y, Lindstrom T. The insulin-like growth factor system in vascular smooth muscle: interaction with insulin and growth factors. Metabolism. 1995 Oct;44(10 Suppl 4):58-66. (Abstract)

20: Bornfeldt KE, Raines EW, Graves LM, Skinner MP, Krebs EG, Ross R. Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann N Y Acad Sci. 1995 Sep 7;766:416-30. (Abstract)

19: Graves LM, Bornfeldt KE, Argast GM, Krebs EG, Kong X, Lin TA, Lawrence JC Jr. cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7222-6. (Abstract)

18: Bornfeldt KE, Graves LM, Raines EW, Igarashi Y, Wayman G, Yamamura S, Yatomi Y, Sidhu JS, Krebs EG, Hakomori S, et al. Sphingosine-1-phosphate inhibits PDGF-induced chemotaxis of human arterial smooth muscle cells: spatial and temporal modulation of PDGF chemotactic signal transduction. J Cell Biol. 1995 Jul;130(1):193-206. (Abstract)

17: Chen Y, Arner A, Bornfeldt KE, Uvelius B, Arnqvist HJ. Development of smooth muscle hypertrophy is closely associated with increased gene expression of insulin-like growth factor binding protein-2 and -4. Growth Regul. 1995 Mar;5(1):45-52. (Abstract)

16: Christoffersen CT, Bornfeldt KE, Rotella CM, Gonzales N, Vissing H, Shymko RM, ten Hoeve J, Groffen J, Heisterkamp N, De Meyts P. Negative cooperativity in the insulin-like growth factor-I receptor and a chimeric IGF-I/insulin receptor. Endocrinology. 1994 Jul;135(1):472-5. (Abstract)

15: Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 1994 Mar;93(3):1266-74. (Abstract)

14: Chen Y, Bornfeldt KE, Arner A, Jennische E, Malmqvist U, Uvelius B, Arnqvist HJ. Increase in insulin-like growth factor I in hypertrophying smooth muscle. Am J Physiol. 1994 Feb;266(2 Pt 1):E224-9. (Abstract)

13: Graves LM, Bornfeldt KE, Raines EW, Potts BC, Macdonald SG, Ross R, Krebs EG. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10300-4. (Abstract)

12: Bornfeldt KE, Skottner A, Arnqvist HJ. In-vivo regulation of messenger RNA encoding insulin-like growth factor-I (IGF-I) and its receptor by diabetes, insulin and IGF-I in rat muscle. J Endocrinol. 1992 Nov;135(2):203-11. (Abstract)

11: Flyvbjerg A, Marshall SM, Frystyk J, Rasch R, Bornfeldt KE, Arnqvist H, Jensen PK, Pallesen G, Orskov H. Insulin-like growth factor I in initial renal hypertrophy in potassium-depleted rats. Am J Physiol. 1992 Jun;262(6 Pt 2):F1023-31. (Abstract)

10: Bornfeldt KE, Arnqvist HJ, Capron L. In vivo proliferation of rat vascular smooth muscle in relation to diabetes mellitus insulin-like growth factor I and insulin. Diabetologia. 1992 Feb;35(2):104-8. (Abstract)

9: Flyvbjerg A, Bornfeldt KE, Orskov H, Arnqvist HJ. Effect of insulin-like growth factor I infusion on renal hypertrophy in experimental diabetes mellitus in rats. Diabetologia. 1991 Oct;34(10):715-20. (Abstract)

8: Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia. 1991 May;34(5):307-13. (Abstract)

7: Flyvbjerg A, Bornfeldt KE, Marshall SM, Arnqvist HJ, Orskov H. Kidney IGF-I mRNA in initial renal hypertrophy in experimental diabetes in rats. Diabetologia. 1990 Jun;33(6):334-8. (Abstract)

6: Bornfeldt KE, Arnqvist HJ, Norstedt G. Regulation of insulin-like growth factor-I gene expression by growth factors in cultured vascular smooth muscle cells. J Endocrinol. 1990 Jun;125(3):381-6. (Abstract)

5: Bornfeldt KE, Arnqvist HJ, Enberg B, Mathews LS, Norstedt G. Regulation of insulin-like growth factor-I and growth hormone receptor gene expression by diabetes and nutritional state in rat tissues. J Endocrinol. 1989 Sep;122(3):651-6. (Abstract)

4: Bornfeldt KE, Arnqvist HJ, Dahlkvist HH, Skottner A, Wikberg JE. Receptors for insulin-like growth factor-I in plasma membranes isolated from bovine mesenteric arteries. Acta Endocrinol (Copenh). 1988 Apr;117(4):428-34. (Abstract)

3: Bornfeldt KE, Arnqvist HJ. Effect of insulin-like growth factor-I on metabolism in bovine mesenteric arteries. Acta Physiol Scand. 1987 Dec;131(4):563-8. (Abstract)

2: Bornfeldt KE, Axelsson KL. Studies on the effect of different inhibitors of arachidonic acid metabolism on glyceryltrinitrate-induced relaxation and cGMP elevation in bovine vascular tissue. Pharmacol Toxicol. 1987 Feb;60(2):110-6. (Abstract)

1: Ahlner J, Axelsson KL, Bornfeldt K. Biological effects of organic nitroesters and their mechanism of action. Acta Pharmacol Toxicol (Copenh). 1986;59 Suppl 6:17-25. (Abstract)